{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:37:08Z","timestamp":1793191028456,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972690"],"award-info":[{"award-number":["81972690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81000914"],"award-info":[{"award-number":["81000914"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Science and Technology Research Project of Health Commission of Henan Province","award":["YXKC2021007"],"award-info":[{"award-number":["YXKC2021007"]}]},{"name":"Medical Science and Technology Research Project of Health Commission of Henan Province","award":["SBGJ202101008"],"award-info":[{"award-number":["SBGJ202101008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00262-022-03259-5","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T18:02:47Z","timestamp":1659722567000},"page":"437-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients"],"prefix":"10.1007","volume":"72","author":[{"given":"Shumin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaokai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongle","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanli","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6882-145X","authenticated-orcid":false,"given":"Zibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"6","key":"3259_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jtho.2020.03","volume":"15","author":"J Remon","year":"2020","unstructured":"Remon J, Passiglia F, Ahn M, Barlesi F, Forde P, Garon E, Gettinger S, Goldberg S, Herbst R, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper K, Skoulidis F, Reck M, Adjei A, Scagliotti G (2020) Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol 15(6):914\u2013947. https:\/\/doi.org\/10.1016\/j.jtho.2020.03","journal-title":"J Thorac Oncol"},{"issue":"4","key":"3259_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L (2018) Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109(4):1207\u20131219. https:\/\/doi.org\/10.1111\/cas.13536","journal-title":"Cancer Sci"},{"issue":"11","key":"3259_CR3","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y (2018) Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol 4(11):1569\u20131575. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039","journal-title":"JAMA Oncol"},{"key":"3259_CR4","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1200\/JCO.2021.39.15_suppl.11505","volume":"39","author":"B Tine","year":"2021","unstructured":"Tine B, Chawla S, Trent J, Wilky B, Chugh R, Chmielowski B, Kummar S, Mallick A, Somaiah N, Cranmer L, Agulnik M, Keedy V, Stacchiotti S, Vincenzi B, Badalamenti G, Siontis B, Attia S (2021) A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma. J Clin Oncol 39:11505. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.11505","journal-title":"J Clin Oncol"},{"issue":"4","key":"3259_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","volume":"16","author":"T Chu","year":"2021","unstructured":"Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Chang Q, Zhang X, Dong Y, Teng J, Gao Z, Qiang H, Nie W, Zhao Y, Han Y, Chen Y, Han B (2021) Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol 16(4):643\u2013652. https:\/\/doi.org\/10.1016\/j.jtho.2020.11.026","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3259_CR6","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00262-021-02869-9","volume":"70","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zeng L, Li Y, Xu Q, Yang H, Lizaso A, Mao X, Jin R, Zeng Y, Li Q, Wang J, Li Y, Zhang Y, Yang N (2021) Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunol Immunother 70(9):2517\u20132528. https:\/\/doi.org\/10.1007\/s00262-021-02869-9","journal-title":"Cancer Immunol Immunother"},{"key":"3259_CR7","doi-asserted-by":"publisher","first-page":"628124","DOI":"10.3389\/fonc.2021.628124","volume":"11","author":"P Wang","year":"2021","unstructured":"Wang P, Fang X, Yin T, Tian H, Yu J, Teng F (2021) Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study. Front Oncol 11:628124. https:\/\/doi.org\/10.3389\/fonc.2021.628124","journal-title":"Front Oncol"},{"issue":"5","key":"3259_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15(5):325\u2013340. https:\/\/doi.org\/10.1038\/nrclinonc.2018.29","journal-title":"Nat Rev Clin Oncol"},{"issue":"43","key":"3259_CR9","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J, Santosuosso M, Martin J, Martin M, Vianello F, Leblanc P, Munn L, Huang P, Duda D, Fukumura D, Jain R, Poznansky M (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109(43):17561\u201317566. https:\/\/doi.org\/10.1073\/pnas.1215397109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3259_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","volume":"21","author":"A Veldt","year":"2012","unstructured":"Veldt A, Lubberink M, Bahce I, Walraven M, Boer M, Greuter H, Hendrikse N, Eriksson J, Windhorst A, Postmus P, Verheul H, Sern\u00e9 E, Lammertsma A, Smit E (2012) Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21(1):82\u201391. https:\/\/doi.org\/10.1016\/j.ccr.2011.11.023","journal-title":"Cancer Cell"},{"issue":"10","key":"3259_CR11","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang Y, Goel S, Duda D, Fukumura D, Jain R (2013) Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73(10):2943\u20132948. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4354","journal-title":"Cancer Res"},{"issue":"4","key":"3259_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","volume":"7","author":"S Zhao","year":"2019","unstructured":"Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, Qiao M, Chen X, Su C, Yu H, Zhou C, Zhang J, Camidge D, Hirsch F (2019) Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer. Cancer Immunol Res 7(4):630\u2013643. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0640","journal-title":"Cancer Immunol Res"},{"key":"3259_CR13","doi-asserted-by":"publisher","first-page":"659380","DOI":"10.3389\/fonc.2021.659380","volume":"11","author":"Q Xiong","year":"2021","unstructured":"Xiong Q, Qin B, Xin L, Yang B, Song Q, Wang Y, Zhang S, Hu Y (2021) Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer. Front Oncol 11:659380. https:\/\/doi.org\/10.3389\/fonc.2021.659380","journal-title":"Front Oncol"},{"issue":"1","key":"3259_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, Chi Y (2016) Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 9(1):105. https:\/\/doi.org\/10.1186\/s13045-016-0332-8","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3259_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"F Detterbeck","year":"2017","unstructured":"Detterbeck F, Boffa D, Kim A, Tanoue L (2017) The eighth edition lung cancer stage classification. Chest 151(1):193\u2013203. https:\/\/doi.org\/10.1016\/j.chest.2016.10.010","journal-title":"Chest"},{"issue":"2","key":"3259_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp K, Baas P, Crin\u00f2 L, Eberhardt W, Poddubskaya E, Antonia S, Pluzanski A, Vokes E, Holgado E, Waterhouse D, Ready N, Gainor J, Frontera O, Havel L, Steins M, Garassino M, Aerts J, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison C, Lestini B, Spigel D (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"issue":"17","key":"3259_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, Chow L, Vokes E, Felip E, Holgado E, Barlesi F, Kohlh\u00e4ufl M, Arrieta O, Burgio M, Fayette J, Lena H, Poddubskaya E, Gerber D, Gettinger S, Rudin C, Rizvi N, Crin\u00f2 L, Blumenschein G, Antonia S, Dorange C, Harbison C, Finckenstein F, Brahmer J (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"issue":"21","key":"3259_CR18","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"C Aggarwal","year":"2015","unstructured":"Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn M, Felip E, Lee J, Hellmann M, Hamid O, Goldman J, Soria J, Dolled-Filhart M, Rutledge R, Zhang J, Lunceford J, Rangwala R, Lubiniecki G, Roach C, Emancipator K, Gandhi L (2015) KEYNOTE-001 Investigators Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"issue":"5","key":"3259_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","volume":"14","author":"Y Wu","year":"2019","unstructured":"Wu Y, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu H, Wu L, Feng J, Zhang J, Luft A, Zhou J, Ma Z, Lu Y, Hu C, Shi Y, Baudelet C, Cai J, Chang J (2019) Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: checkMate 078 randomized phase III clinical trial. J Thorac Oncol 14(5):867\u2013875. https:\/\/doi.org\/10.1016\/j.jtho.2019.01.006","journal-title":"J Thorac Oncol"},{"key":"3259_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lungcan.2020.11.013","volume":"152","author":"S Lu","year":"2021","unstructured":"Lu S, Wang J, Cheng Y, Mok T, Chang J, Zhang L, Feng J, Tu H, Wu L, Zhang Y, Luft A, Zhou J, Ma Z, Lu Y, Hu C, Shi Y, Ying K, Zhong H, Poddubskaya E, Soo R, Chia Y, Li A, Li A, Wu Y (2021) Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). Lung Cancer 152:7\u201314. https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.013","journal-title":"Lung Cancer"},{"key":"3259_CR21","doi-asserted-by":"publisher","first-page":"683502","DOI":"10.3389\/fonc.2021.683502","volume":"11","author":"M Yuan","year":"2021","unstructured":"Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X, Xu Q (2021) Anlotinib combined with anti-PD-1 antibodies therapy in patients with advanced refractory solid tumors: a single-center, observational, prospective study. Front Oncol 11:683502. https:\/\/doi.org\/10.3389\/fonc.2021.683502","journal-title":"Front Oncol"},{"key":"3259_CR22","doi-asserted-by":"publisher","first-page":"619010","DOI":"10.3389\/fonc.2020.619010","volume":"10","author":"C Zhai","year":"2021","unstructured":"Zhai C, Zhang X, Ren L, You L, Pan Q, Pan H, Han W (2021) The Efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer. Front Oncol 10:619010. https:\/\/doi.org\/10.3389\/fonc.2020.619010","journal-title":"Front Oncol"},{"issue":"4","key":"3259_CR23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","volume":"28","author":"Y Su","year":"2022","unstructured":"Su Y, Luo B, Lu Y, Wang D, Yan J, Zheng J, Xiao J, Wang Y, Xue Z, Yin J, Chen P, Li L, Zhao Q (2022) Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD1 checkpoint blockade in neuroblastoma. Clin Cancer Res 28(4):793\u2013809. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2241","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3259_CR24","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","volume":"69","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li L, Jiang Z, Wang B, Pan Z (2020) Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother 69(12):2523\u20132532. https:\/\/doi.org\/10.1007\/s00262-020-02641-5","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03259-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03259-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T14:04:40Z","timestamp":1674482680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03259-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3259"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03259-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is an observational study. The ethics committees of the Affiliated Cancer Hospital of Zhengzou University & Henan Cancer Hospital has confirmed that no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the retrospective nature of the study and because no patient specimens were used, the requirement for informed consent was waived by the ethics committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}